Platinum-ineligible: atezolizumab preferable
Crossref DOI link: https://doi.org/10.1038/s41571-023-00806-6
Published Online: 2023-07-21
Published Print: 2023-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Killock, David
Text and Data Mining valid from 2023-07-21
Version of Record valid from 2023-07-21
Article History
First Online: 21 July 2023